Phase II Study of PET-Guided Treatment and Blood Monitoring for Newly Diagnosed Limited Stage Diffuse Large B Cell Lymphoma

What this Trial Is About

This research aims to measure circulating tumor DNA ctDNA levels in patients with early stage diffuse large B cell lymphoma DLBCL to identify markers of treatment failure and to explore ctDNAs use for response-adapted therapy. The study also investigates the relationship between FDG-PET scans and minimal residual disease MRD measured by ctDNA in these patients. Participants will receive standard chemoimmunotherapy using the R-CHOP regimen followed by radiation based on established protocols, without radioimmunotherapy. Treatment response will be evaluated using the Deauville criteria via PET scans. Non-invasive ctDNA monitoring will occur at diagnosis and at specific times after therapy completion. During the study, participants will undergo blood tests, physical exams, and PET scans to assess treatment response and ctDNA levels. Quality of life will be measured periodically using the PROMIS scale. Follow-up visits will continue for up to five years to monitor overall survival, progression-free survival, and treatment side effects, ensuring comprehensive assessment of treatment outcomes and safety.

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma